These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 30630983)

  • 1. CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.
    Prieto-Torres L; Rodriguez-Pinilla SM; Onaindia A; Ara M; Requena L; Piris MÁ
    Haematologica; 2019 Feb; 104(2):226-235. PubMed ID: 30630983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD30-Positive Lymphoproliferative Disorders.
    Nikolaenko L; Zain J; Rosen ST; Querfeld C
    Cancer Treat Res; 2019; 176():249-268. PubMed ID: 30596222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How I treat primary cutaneous CD30
    Shinohara MM; Shustov A
    Blood; 2019 Aug; 134(6):515-524. PubMed ID: 31164331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.
    Di Raimondo C; Parekh V; Song JY; Rosen ST; Querfeld C; Zain J; Martinez XU; Abdulla FR
    Curr Hematol Malig Rep; 2020 Aug; 15(4):333-342. PubMed ID: 32435988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nodal Involvement by CD30
    Lezama LS; Gratzinger D
    Arch Pathol Lab Med; 2018 Jan; 142(1):139-142. PubMed ID: 29257929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.
    Bhabha FK; McCormack C; Campbell BA; Lade S; Buelens O; Van Der Weyden C; Prince HM
    Australas J Dermatol; 2023 May; 64(2):194-203. PubMed ID: 36892928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment.
    Bekkenk MW; Geelen FA; van Voorst Vader PC; Heule F; Geerts ML; van Vloten WA; Meijer CJ; Willemze R
    Blood; 2000 Jun; 95(12):3653-61. PubMed ID: 10845893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
    Kartan S; Johnson WT; Sokol K; Alpdogan O; Gru AA; Nikbakht N; Porcu P
    Chin Clin Oncol; 2019 Feb; 8(1):3. PubMed ID: 30691273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of Primary Cutaneous CD30
    Chen C; Gu YD; Geskin LJ
    Hematol Oncol Clin North Am; 2019 Feb; 33(1):121-134. PubMed ID: 30497669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
    Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
    Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case-Based Review of Cutaneous CD30-Positive Lymphoproliferative Disorders.
    Felts C; Tjarks BJ
    S D Med; 2022 Sep; 75(9):402-409. PubMed ID: 36881825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation.
    Davick JJ; Mutgi KAJ; Wanat KA; Link BK; Liu V
    J Cutan Pathol; 2017 Aug; 44(8):703-712. PubMed ID: 28497585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype.
    Kummer JA; Vermeer MH; Dukers D; Meijer CJ; Willemze R
    J Invest Dermatol; 1997 Nov; 109(5):636-40. PubMed ID: 9347791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DUSP22-IRF4 Rearranged CD30-Positive Primary Cutaneous Lymphoproliferative Disorder With Gamma/Delta Phenotype.
    Fattah YH; Crasto D; Liu SS; Linhares Y; Kerdel F; Hanly A; Karai LJ
    Am J Dermatopathol; 2023 Dec; 45(12):831-834. PubMed ID: 37883980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment.
    Willemze R; Beljaards RC
    J Am Acad Dermatol; 1993 Jun; 28(6):973-80. PubMed ID: 8388410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders.
    Sciallis AP; Law ME; Inwards DJ; McClure RF; Macon WR; Kurtin PJ; Dogan A; Feldman AL
    Mod Pathol; 2012 Jul; 25(7):983-92. PubMed ID: 22388754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators.
    Kempf W
    J Cutan Pathol; 2006 Feb; 33 Suppl 1():58-70. PubMed ID: 16412214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary cutaneous CD30(+) lymphoproliferative disorders.
    Wieser I; Tetzlaff MT; Torres Cabala CA; Duvic M
    J Dtsch Dermatol Ges; 2016 Aug; 14(8):767-82. PubMed ID: 27509411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD30+ lymphoproliferative disorders of the skin: still an open question.
    Alaibac M; Zarian H; Russo I; Peserico A
    G Ital Dermatol Venereol; 2012 Dec; 147(6):545-52. PubMed ID: 23149700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD30+ T-cell lymphoproliferative disorders.
    Martin JM; Wu H; Barta SK
    Chin Clin Oncol; 2019 Feb; 8(1):4. PubMed ID: 30525751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.